NCT05775575View on ClinicalTrials.gov

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Advanced Breast Cancer
Interventions
DRUG

TQB3909 tablets

TQB3909 is an inhibitor targeting BCL-2 protein

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY